Endocyte (ECYT) Removed from Wedbush's Best Ideas List
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Endocyte Reports First Quarter Financial Results and Provides Clinical Update
May 2, 2014 8:01 AM EDT- Independent DSMB Recommends to Stop Phase 3 PROCEED Trial for Futility Following Interim Analysis
- Endocyte Initiates Phase 1 Trial of PSMA-Targeted Tubulysin SMDC (EC1169) in Prostate Cancer Following FDA Acceptance of IND
- Conference Call Today at 8:30 a.m. EDT
WEST LAFAYETTE, Ind., May 2, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq: ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy,... More
